Optimal Effective Local Anesthetic Volume for Pain Relief Using Brachial Plexus Block

Benaroya Research Institute

Status and phase: Enrolling; Phase 4

Conditions: Post Operative Pain

Treatments: Drug: Dose of 0.5% Ropivacaine

Study type: Interventional

Funder types: Other

Identifiers

NCT05868993

IRB20-018

Details and patient eligibility

About

Prospective, patient-blinded study utilizing a novel Continuous Reassessment Method that concomitantly considers both block success and block side effects (lung dysfunction) for brachial plexus nerve blocks.

Full description

Success or failure of the brachial plexus block for any given volume will be determined by the verbal analogue pain scale score obtained 60 minutes after surgical end time. Volumes will be determined by continuous reassessment method.

Enrollment: 150 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Surgical candidate for Arthroscopic rotator cuff surgery
• ASA I-III
• BMI<40
• Age >18

Exclusion criteria

• Inability to give informed consent
• Inability to complete consent process in English
• allergy to ropivacaine
• neuropathy
• contraindications to peripheral nerve block per ASRA guidelines
• chronic opioid use
• infection at the injection/catheter site
• limb restriction due to medical history
• history of moderate - severe lung disease.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

150 participants in 3 patient groups

Brachial Plexus Block Group 1

Experimental group

Description:

Interscalene

Treatment:

Drug: Dose of 0.5% Ropivacaine

Brachial Plexus Group 2

Experimental group

Description:

Supraclavicular

Treatment:

Drug: Dose of 0.5% Ropivacaine

Brachial Plexus Group 3

Experimental group

Description:

Suprascapular

Treatment:

Drug: Dose of 0.5% Ropivacaine